Members

  First name: Gilles
  Last name: Collin
  Function: Medical engineer, researcher
  Position: Medical engineer
  Email: gilles.collin
._
_.
aphp.fr

Research interest


My main field of interest is HIV physiopathology and resistance. My time is distributed between the development of research assay on these fields and by the testing and application of commercial assays in the laboratory of medical virology at the university hospital Bichat Claude Bernard. I actively developed the ANRS consensual protocol for phenotypic and genotypic testing of HIV sensitivity to antiretroviral drugs. Today, I also participate to the development of the Papillomavirus thematic in our research team. In this context I develop new approaches to detect and sequence this virus in order to better characterize its diversity and physiopathology.

Education

Degree

1997: Engineering degree, Conservatoire National des Arts et Métiers, Paris
1985: Technical diploma graduate, Conservatoire National des Arts et Métiers, Paris
1983: Biochemical technical cycle degree, Conservatoire National des Arts et Métiers, Paris
1979: Medical biology technician certificate, Ecole Supérieure de Biologie et de Biochimie, Paris

Academic positions

2000-today: Research and medical biology engineer, Laboratory of Virology, Hospital Bichat Claude Bernard, Paris
1991-2000: Research technician in therapeutic trials, Hospital Bichat Claude Bernard, Paris
1980-1990: Medical biology technician, Laboratory of Virology, Hospital Bichat Claude Bernard, Paris

Research training (post doctoral)

1996: University diploma in Molecular Biology, University Pierre and Marie Curie, Paris
1995: University diploma in ADN analysis by PCR, University Pierre and Marie Curie, Paris

List of the main publications

Benmoussa N, Charpentier C, Mariaggi AA, Collin G, Descamps D, Hourseau M, Barry B, Albert S, Picard A, Conan P, Charlier P
HPV 16 in squamous cell carcinoma of 19th century tonsils.
The Lancet. Oncology 2016, 17, e477–e478.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D, ACH2C
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
PloS One 2015, 10, e0134904.

Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, Nie T, Schinazi R, Brun-Vézinet F, Descamps D, FAH2C(C0V2
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
AIDS (London, England) 2010, 24, 2753-2755.

Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, Campa P, Benard A, Chêne G, Brun-Vezinet F
Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.
Journal of Clinical Microbiology 2005, 43, 4234-4236.


Exhaustive list of publications

2022


Lebourgeois S, Menidjel R, Chenane HR, Ferré VM, Collin G, Damond F, Coppée R, Yazdanpanah Y, Timsit JF, Houhou-Fidouh N, Descamps D, Charpentier C, Visseaux B
Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
The Journal of Infection 2022, 84, 418-467.

Ferré VM, Lebourgeois S, Chenane HR, Menidjel R, Masson C, Collin G, Visseaux B, Descamps D, Fidouh N, Charpentier C
Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.
The Journal of Infection 2022, S0163-4453(22)00126-8.

Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, Collin G, Namour C, Assoun S, Bizot A, Brouk Z, Vicaut E, Teixeira L, Descamps D, Zalcman G
Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2022, 17, 239-251.

Le Hingrat Q, Collin G, Damond F, Peytavin G, Lebourgeois S, Ghosn J, Bachelard A, Ferré VM, Matheron S, Descamps D, Charpentier C
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions.
The Journal of Antimicrobial Chemotherapy 2022, 77, 409-412.

Le Hingrat Q, Collin G, Bachelard A, Ghosn J, Chalal S, Pacanowski J, Peytavin G, Weinheimer S, Marsolais C, Damond F, Matheron S, Charpentier C, Descamps D, atACH2c
Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates.
AIDS (London, England) 2022

2021


Lemaitre F, Fily F, Foulquier JB, Revest M, Jullien V, Petitcollin A, Tattevin P, Tron C, Polard JL, Verdier MC, Comets E, Huten D, Arvieux C, Bellissant E, Laviolle B
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 2021, 142, 112053.

Martin A, Storto A, Le Hingrat Q, Collin G, André B, Mallory A, Dangla R, Descamps D, Visseaux B, Gossner O
High-sensitivity SARS-CoV-2 group testing by digital PCR among symptomatic patients in hospital settings.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2021, 141, 104895.

Ferré VM, Lebourgeois S, Menidjel R, Collin G, Chenane HR, Guindi MO, Yazdanpanah Y, Timsit JF, Charpentier C, Descamps D, Fidouh N, Visseaux B
Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.
The Journal of Infection 2021, S0163-4453(21)00488-6.

Visseaux B, Collin G, Houhou-Fidouh N, Le Hingrat Q, Ferré VM, Damond F, Ichou H, Descamps D, Charpentier C
Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements.
Journal of Virological Methods 2021, 291, 114086.

Diallo MS, Samri A, Charpentier C, Bertine M, Cheynier R, Thiébaut R, Matheron S, Collin F, Braibant M, Candotti D, Brun-Vézinet F, Autran B, ACI2aACASG
A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors.
AIDS research and human retroviruses 2021, 37, 214-223.

Visseaux B, Bertine M, Le Hingrat Q, Ferré V, Charpentier C, Collin F, Damond F, Matheron S, Hué S, Descamps D
HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution.
Virus Evolution 2021, 7, veab024.

Lebourgeois S, Chenane HR, Houhou-Fidouh N, Menidjel R, Ferré VM, Collin G, Benmalek N, Coppée R, Larrouy L, Yazdanpanah Y, Timsit JF, Charpentier C, Descamps D, Visseaux B
Earlier In Vitro Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants.
Frontiers in Cellular and Infection Microbiology 2021, 11, 792202.

Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E
Impact of Low-Dose Methotrexate-Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis.
Vaccines 2021, 9, 883.

Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E
Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.
Vaccines 2021, 9, 1140.

2020


Battesti G, El Khalifa J, Abdelhedi N, Ferre V, Bouscarat F, Picard-Dahan C, Brunet-Possenti F, Collin G, Lavaud J, Le Bozec P, Rousselot M, Tournier A, Lheure C, Couvelard A, Hacein-Bey-Abina S, Abina AM, Charpentier C, Mignot S, Nicaise P, Descamps D, Deschamps L, Descamps V
New insights in COVID-19–associated chilblains: A comparative study with chilblain lupus erythematosus.
Journal of the American Academy of Dermatology 2020, 83, 1219-1222.

Visseaux B, Le Hingrat Q, Collin G, Ferré V, Storto A, Ichou H, Bouzid D, Poey N, de Montmollin E, Descamps D, Houhou-Fidouh N
Evaluation of the RealStar® SARS-CoV-2 RT-PCR kit RUO performances and limit of detection.
Journal of Clinical Virology 2020, 129, 104520.

Egloff C, Tassin M, Bault JP, Barjol A, Collin A, Simon I, Sibiude J, Mandelbrot L, Picone O
Prenatal description of retinal coloboma.
Journal of Gynecology Obstetrics and Human Reproduction 2020, 49, 101746.

Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Lê MP, Katlama C, Collin G, Benalycherif A, Cabie A, Mentré F, Yazdanpanah Y, Descamps D, Joly V
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
The Journal of Antimicrobial Chemotherapy 2020, 75, 1611-1617.

Visseaux B, Le Hingrat Q, Collin G, Bouzid D, Lebourgeois S, Le Pluart D, Deconinck L, Lescure FX, Lucet JC, Bouadma L, Timsit JF, Descamps D, Yazdanpanah Y, Casalino E, Houhou-Fidouh N, McAdam AJ
Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection.
Journal of Clinical Microbiology 2020, 58, e00630-20, /jcm/58/8/JCM.00630-20.atom.

Le Hingrat Q, Visseaux B, Bertine M, Chauveau L, Schwartz O, Collin F, Damond F, Matheron S, Descamps D, Charpentier C
Genetic Variability of Long Terminal Repeat Region between HIV-2 Groups Impacts Transcriptional Activity.
Journal of Virology 2020, 94,

Le Hingrat Q, Ghanem M, Cazes A, Visseaux B, Collin G, Descamps D, Charpentier C, Crestani B
No association between human herpesvirus or herpesvirus saimiri and idiopathic pulmonary fibrosis.
ERJ Open Research 2020, 6, 00243-2020.

2019


Ferré V, Ekouevi D, Gbeasor-Komlanvi F, Collin G, Le Hingrat Q, Tchounga B, Salou M, Descamps D, Charpentier C, Dagnra A
Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey.
Clinical Microbiology and Infection 2019, 25, 1560.e1-1560.e7.

Ferré VM, Gbeasor-Komlanvi FA, Collin G, Dagnra AC, Le Hingrat Q, Jaquet A, Salou M, Descamps D, Charpentier C, Ekouevi DK
Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 1019-1026.

Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A, Bernard L, Damond F, Matheron S, Descamps D, Charpentier C, FNAfRoAaVH(CH2C
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 657-667.

Samri A, Charpentier C, Diallo MS, Bertine M, Even S, Morin V, Oudin A, Parizot C, Collin G, Hosmalin A, Cheynier R, Thiébaut R, Matheron S, Collin F, Zoorob R, Brun-Vézinet F, Autran B, ACI2SG
Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection.
PLoS pathogens 2019, 15, e1007758.

2018


Le Hingrat Q, Perrier M, Collin G, Drumard S, Storto A, Bertine M, Larrouy L, Matheron S, Damond F, Charpentier C, Descamps D, Visseaux B
Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads.
Journal of Virological Methods 2018, 257, 12-15.

Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, Mortier E, Charpentier C, Tubiana R, Damond F, Peytavin G, Ponscarme D, Collin F, Brun-Vezinet F, Chene G, A1H2tSG
First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018

Mariaggi AA, Péré H, Perrier M, Visseaux B, Collin G, Veyer D, Hingrat QL, Ferré VM, Joly V, Couvelard A, Bucau M, Davitian C, Descamps D, Abramowitz L, Charpentier C
Presence of HPV APOBEC-related Minority Variants in HPV16 Genomes from Anal and Cervical Samples but not in HPV52 and HPV58.
The Journal of Infectious Diseases 2018

Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C, AH2CC
Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2018

Brunet-Possenti F, Charpentier C, Collin G, Descamps D, Descamps V
Impact of anti-interleukin-17 treatment on cutaneous and genital human papillomavirus infection.
The British Journal of Dermatology 2018, 179, 1179-1180.

2017


Alessandri-Gradt E, Collin G, Tourneroche A, Bertine M, Leoz M, Charpentier C, Unal G, Descamps D, Plantier JC
HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2431-2437.

Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, Landman R, Yazdanpanah Y, Descamps D, Charpentier C
Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2954-2955.

Bertine M, Gueudin M, Mélard A, Damond F, Descamps D, Matheron S, Collin F, Rouzioux C, Plantier JC, Avettand-Fenoel V
New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.
Journal of Clinical Microbiology 2017, 55, 2850-2857.

Malet I, Subra F, Charpentier C, Collin G, Descamps D, Calvez V, Marcelin AG, Delelis O
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
mBio 2017

Visseaux B, Collin G, Ichou H, Charpentier C, Bendhafer S, Dumitrescu M, Allal L, Cojocaru B, Desfrère L, Descamps D, Mandelbrot L, Houhou-Fidouh N
Usefulness of multiplex PCR methods and respiratory viruses' distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study.
PloS One 2017, 12, e0172809.

2016


Benmoussa N, Charpentier C, Mariaggi AA, Collin G, Descamps D, Hourseau M, Barry B, Albert S, Picard A, Conan P, Charlier P
HPV 16 in squamous cell carcinoma of 19th century tonsils.
The Lancet. Oncology 2016, 17, e477–e478.

Visseaux B, Mortier E, Houhou-Fidouh N, Brichler S, Collin G, Larrouy L, Charpentier C, Descamps D
Zika virus in the female genital tract.
The Lancet. Infectious Diseases 2016, 16, 1220.

Njamkepo E, Fawal N, Tran-Dien A, Hawkey J, Strockbine N, Jenkins C, Talukder KA, Bercion R, Kuleshov K, Kolínská R, Russell JE, Kaftyreva L, Accou-Demartin M, Karas A, Vandenberg O, Mather AE, Mason CJ, Page AJ, Ramamurthy T, Bizet C, Gamian A, Carle I, Sow AG, Bouchier C, Wester AL, Lejay-Collin M, Fonkoua MC, Hello SL, Blaser MJ, Jernberg C, Ruckly C, Mérens A, Page AL, Aslett M, Roggentin P, Fruth A, Denamur E, Venkatesan M, Bercovier H, Bodhidatta L, Chiou CS, Clermont D, Colonna B, Egorova S, Pazhani GP, Ezernitchi AV, Guigon G, Harris SR, Izumiya H, Korzeniowska-Kowal A, Lutyńska A, Gouali M, Grimont F, Langendorf C, Marejková M, Peterson LAM, Perez-Perez G, Ngandjio A, Podkolzin A, Souche E, Makarova M, Shipulin GA, Ye C, Žemličková H, Herpay M, Grimont PAD, Parkhill J, Sansonetti P, Holt KE, Brisse S, Thomson NR, Weill FX
Global phylogeography and evolutionary history of Shigella dysenteriae type 1.
Nature Microbiology 2016, 1, 16027.

Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C, ACH2C
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.

2015


Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D, ACH2C
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
PloS One 2015, 10, e0134904.

2014


Avettand-Fenoel V, Damond F, Gueudin M, Matheron S, Mélard A, Collin G, Descamps D, Chaix ML, Rouzioux C, Plantier JC, ACH2atAAQWG
New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load.
Journal of Clinical Microbiology 2014, 52, 3017–3022.

2013


Bidet P, Collin E, Basmaci R, Courroux C, Prisse V, Dufour V, Bingen E, Grimprel E, Bonacorsi S
Investigation of an outbreak of osteoarticular infections caused by Kingella kingae in a childcare center using molecular techniques.
The Pediatric Infectious Disease Journal 2013, 32, 558-560.

Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D
In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
AIDS (London, England) 2013, 27, 2959-2961.

2012


Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F, FAH2CC
Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2012, 55, 1417-1425.

Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, AC0H2C
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
The Journal of Infectious Diseases 2012, 205, 111-120.

Lamiraud K, Moatti JP, Raffi F, Carrieri MP, Protopopescu C, Michelet C, Schneider L, Collin F, Leport C, Spire B
Adherence to and effectiveness of highly active antiretroviral treatment for HIV infection: assessing the bidirectional relationship.
Medical Care 2012, 50, 410–418.

Lada O, Gervais A, Branger M, Peytavin G, Roquebert B, Collin G, Fraqueiro G, Moucari R, Hamet G, Martinot-Peignoux M, Matheron S, Marcellin P
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Liver International: Official Journal of the International Association for the Study of the Liver 2012, 32, 93-101.

Lada O, Gervais A, Branger M, Peytavin G, Roquebert B, Collin G, Fraqueiro G, Moucari R, Leclerc L, Martinot-Peignoux M, Matheron S, Marcellin P
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Antiviral Therapy 2012, 17, 61-70.

2011


Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D, FAH2C(C0V2
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
Antimicrobial Agents and Chemotherapy 2011, 55, 1293-1295.

Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Retrovirology 2011, 8, 68.

2010


Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, Nie T, Schinazi R, Brun-Vézinet F, Descamps D, FAH2C(C0V2
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
AIDS (London, England) 2010, 24, 2753-2755.

Depatureaux A, Charpentier C, Collin G, Leoz M, Descamps D, Vessière A, Damond F, Rousset D, Brun-Vézinet F, Plantier JC
Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.
Antimicrobial Agents and Chemotherapy 2010, 54, 4016-4019.

Damond F, Avettand-Fenoel V, Collin G, Roquebert B, Plantier JC, Ganon A, Sizmann D, Babiel R, Glaubitz J, Chaix ML, Brun-Vezinet F, Descamps D, Rouzioux C
Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification.
Journal of Clinical Microbiology 2010, 48, 1413-1416.

2009


Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, Villes V, Chêne G, Raffi F, ACACsg
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults.
AIDS (London, England) 2009, 23, 1021-1024.

Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun-Vezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C
The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection.
Journal of Virology 2009, 83, 4854-4860.

Peretti-Watel P, Villes V, Duval X, Collin F, Reynes J, Sobel A, Protopopescu C, Chêne G, Spire B, Raffi F, ACACsg
How do HIV-infected smokers react to cigarette price increases? Evidence from the APROCO-COPILOTE-ANRS CO8 Cohort.
Current HIV research 2009, 7, 462-467.

2008


Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C0V2
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
The Journal of Antimicrobial Chemotherapy 2008, 62, 914-920.

Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, AH2CC
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
AIDS (London, England) 2008, 22, 2045-2046.

Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, Campa P, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C0V2
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Antimicrobial Agents and Chemotherapy 2008, 52, 1545-1548.

2007


Damond F, Roquebert B, Bénard A, Collin G, Miceli M, Yéni P, Brun-Vezinet F, Descamps D
Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays.
Journal of Clinical Microbiology 2007, 45, 3436-3438.

2006


Descamps D, Ait-Khaled M, Craig C, Delarue S, Damond F, Collin G, Brun-Vézinet F
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Antiviral Therapy 2006, 11, 701-705.

2005


Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, Campa P, Benard A, Chêne G, Brun-Vezinet F
Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.
Journal of Clinical Microbiology 2005, 43, 4234-4236.

Damond F, Collin G, Matheron S, Peytavin G, Campa P, Delarue S, Taieb A, Bénard A, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C5V2
Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.
Antiviral Therapy 2005, 10, 861-865.

2004


Lastere S, Dalban C, Collin G, Descamps D, Girard PM, Clavel F, Costagliola D, Brun-Vezinet F, NTG(0
Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
Antiviral Therapy 2004, 9, 221-227.

1995


Descamps D, Collin G, Loussert-Ajaka I, Saragosti S, Simon F, Brun-Vézinet F
HIV-1 group O sensitivity to antiretroviral drugs.
AIDS (London, England) 1995, 9, 977-978.